Ashish Jain is Vice President, global Early Clinical Development at QuintilesIMS. He is responsible for growing the business across Asia-Pacific, the U.S. and Europe. Ashish developed and implemented the global Early Clinical Development partner site network solution across Asia, Europe and the U.S. to cater to the growing customer needs for conducting early clinical studies in healthy volunteers, patient populations and/or in both healthy volunteers and patients. Ashish spends time with customers to understand and offer solutions to meet their needs, including interacting with global customers wanting to externalize products from their home countries into the Asia-Pacific market. Similarly, he also works with customers in their drug development efforts and who are looking for advice and guidance on QuintilesIMS’s early clinical development capabilities in the U.S. and Europe.
Ashish has more than 19 years of experience in the early clinical space including the bioanalytical and clinical laboratory areas as well as scientific operations. Further, Ashish has an extensive background in establishing multiple new clinical research units including QuintilesIMS’s state-of-the-art Phase 1 unit in Hyderabad, India. He has also built businesses, acquired a CRO in North America and has integrated businesses across different continents.
Prior to moving to the U.S., Ashish was based in Singapore heading QuintilesIMS’s Early Clinical Development business in Asia-Pacific. Ashish completed his post graduate degree in Pharmacy from the Birla Institute of Technology and Science (BITS) in Pilani, India.